What is the physiological, safety, efficacy and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this impact FPG and PPG control?
What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?
What are the translational implications of the LEADER trial based on the results reported at ADA 2016?
Can you review for us the design and rationale of the LEADER trial?
How do make sense of the results and designs of the various cardiovascular outcome trials, including the LEADER trial, in patients with T2D and what do you believe is the take home message?
What are the important developments at ADA 2016 as far as GLP-1 RAs?
What patients with T2D are most likely to benefit from fixed-ratio combinations such a iDegLira and iGlarLixi?
Can you provide a roadmap for how insulin plus GLP-1 RA combination formulations should be titrated?
From a practical perspective, how should clinicians titrate the fixed-ratio combinations such a iDegLira and iGlarLixi?
What is the rationale for combining a basal insulin and GLP-1 RA in a fixed-ratio formulation?
How effective was the glycemic control achieved in the GLP-1 RA treatment arm of the LEADER trial?
What do you speculate might be the most important mechanistic explanations for the reduction in CV events reported with liraglutide in the LEADER trial?